Vanda spikes on FDA priority review for rare sleep disorder drug
This article was originally published in Scrip
Executive Summary
Investors got behind Vanda Pharmaceuticals in a big way on 30 July, driving shares up as high as 47%, after the Washington-based company revealed the FDA had not only accepted the firm's new drug application (NDA) for tasimelteon to treat a certain type of sleep-wake condition, known as non-24-Hour disorder, but also granted it a priority review.